Both posters will be available on the Rectify website at https://rectifypharma.com/publications/.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...

Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, ...

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the “Hearings Panel”) has cancelled ...

The presentation entitled, “ Safety and Efficacy Data from a Phase I Trial of Umbilical Lining Stem Cells (ULSCs) in Adult Dermatomyositis/Polymyositis ” was delivered by Michael R Bubb, M.D., ...

HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and ...

We are pleased to complete the last subject visit in our Phase 1 trial of MBX 1416 in healthy adults and extend our sincere appreciation to the participants, investigators and clinical team for their ...

The private placement was led by Vivo Capital, with participation by new and existing investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital ...

The Company strongly encourages all of its stockholders to read the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on October 18, ...

We view our listing on Nasdaq to be extremely important to us as a Company as it offers the Company and its shareholders the best opportunity for the future. Further, we want to thank the shareholders ...

A special digital timeline has been created to celebrate this milestone.

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancer; Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate st ...